Overview

Beacon Everolimus Xevirol 5mg tablets represent a high-volume, multi-indication generic oncology asset demanding structured procurement planning. As an oral mTORC1 inhibitor with approvals spanning HR-positive breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumors, and TSC-associated indications, Xevirol serves both solid tumor and rare disease segments simultaneously. For procurement managers, this breadth translates into diversified demand streams reducing inventory obsolescence risk compared to single-indication oncology products. Beacon operates WHO-GMP-certified production lines in Bangladesh, and the finished dosage form is ambient-stable, eliminating cold-chain complexity. The key procurement challenge lies in quality verification depth for a complex macrocyclic lactone molecule with multiple stereogenic centers.

How It Works

From a supply chain perspective, everolimus procurement requires understanding the API synthesis pathway and critical quality attributes. The molecule is a semi-synthetic sirolimus derivative produced through selective O-alkylation at the C-40 hydroxyl position. Key quality risks include incomplete purification of sirolimus starting material, introducing homologous impurities, and ring-opening degradation generating seco-everolimus species. Procurement contracts should specify batch certificates demonstrating HPLC purity ≥99.0%, individual specified impurities below 0.10%, and total impurities below 0.5%. The stable crystalline polymorphic form should be confirmed by XRPD to exclude amorphous content exceeding 5%.

Indications

Xevirol's commercial value derives from its label spanning five oncology and rare disease indications. A single SKU supplies multiple hospital departments — medical oncology for breast cancer and RCC, endocrinology for pancreatic neuroendocrine tumors, neurology for subependymal giant cell astrocytoma, and nephrology or genetics clinics for TSC-associated renal angiomyolipoma. This departmental diversity reduces commercial risk from formulary changes in any single therapeutic area. The 10-tablet blister pack enables flexible dispensing for both the 10 mg standard dose and 5 mg reduced dose.

Dosage & Administration

The standard dose is 10 mg once daily (two 5 mg tablets). Procurement planning should account for approximately 1.6 tablets per patient-day, reflecting the mix of full-dose, reduced-dose, and temporarily interrupted patients. A hospital with 50 active patients would consume roughly 80 tablets daily, or 240 blister packs monthly. Importers should maintain 6–8 weeks of safety stock against 8–12 week manufacturing lead times.

Storage & Sourcing

Xevirol 5mg tablets are packaged in aluminum-aluminum cold-form blister strips of 10. Store at 20–25°C, protected from light and moisture. Shelf life is 24 months.

FAQ.

Q: What distinguishes this Xevirol listing from other everolimus SKU variants? This listing represents a specific Beacon production line batch series with its own DMF reference and stability program. Different SKUs may correspond to different manufacturing sites, packaging configurations, or registered markets..

Q: How should procurement managers structure quality agreements for generic everolimus? Quality agreements should mandate annual stability testing on at least one production batch, notification within 30 days of any OOS result or process change, and provision of the annual product quality review. For markets requiring bioequivalence data, specify the complete pharmacokinetic study report with 90% CIs for Cmax and AUC within 80–125%.

Q: What are the typical lead time and payment terms for Beacon Xevirol? Standard lead time is 8–12 weeks from PO to ex-works readiness, plus 4–6 weeks for sea freight. Payment terms are typically 100% advance TT or 50% advance with 50% against shipping documents..